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inTRODUCTiOn
Because of the rapid emotional and endocrine changes in the postpartum period (1), postpar-
tum mood disorders represent the most frequent form of maternal psychiatric morbidity (2–4). 
Postpartum mood disorders vary from a mild form of transient depression (maternity blues) to full-
blown postpartum depression and severe psychosis (5, 6). Postpartum depression affects 10–30% 
of women within 1 year after delivery (7), and its risk is measurable already at 3 (8) or 7 days (2) 
postpartum. This risk predicts depression development in the following months (9, 10).
Thyroid function abnormalities exhibit comorbidity with various psychiatric disorders, including 
maternal depression. There are one-tenth of a million studies on mood disorders, but fewer than 
5,000 (3.9% of almost 125,000) concern mood disorders in the postpartum period. Similarly, studies 
on autoimmune thyroid disease are almost 20,000, but only 72 (3.7% of 19,360) concern postpartum 
mood disorders and thyroid disorders, and merely 5 focus on postpartum mood disorders and 
thyroid autoimmunity. Thus, we hope that our opinion will stimulate interest.
pOSTpARTUM AFFECTiVE DiSORDERS AnD THYROiD 
DYSFUnCTiOn
Affective disorders and autoimmune thyroiditis are well known to affect women during puerperium. 
Up to 23% of all new mothers experiences thyroid dysfunction postpartum (11), compared with a 
prevalence of 3–4% in the general population (12). Maternal thyroid autoimmunity refers to the 
detection of thyroid autoantibodies against thyroperoxidase (TPOAb) and/or thyroglobulin (TgAb) 
in combination with normal thyroid function, and it has been reported to affect between 8 and 14% 
women in reproductive age (13). Concerning positivity for TPOAb, approximately 10% of pregnant 
women are TPOAb positive, and around one-third to half of them will develop postpartum thyroidi-
tis (PPT) within 12 months after delivery (11, 14).
At least 2–3% of women have some form of thyroid dysfunction during pregnancy, and 10–17% 
of women have thyroid autoimmune disease despite euthyroidism (15, 16). Thyroid dysfunction in 
pregnancy is classified as (i) primary overt hypothyroidism (elevated TSH and a decreased FT4 dur-
ing gestation with both concentrations outside the trimester-specific reference ranges) or subclinical 
hypothyroidism (with a TSH elevated beyond the upper limit of the pregnancy-specific reference 
range); (ii) hyperthyroidism (autoimmune Graves’ disease or gestational transient thyrotoxicosis) 
(17); and (iii) positivity of thyroid autoantibodies, which increases the risk of thyroid dysfunction 
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following delivery and during the postpartum period. PPT is 
an inflammatory autoimmune condition, which occurs within 
the first year after delivery or miscarriage (a period when the 
immunosuppressive effect of pregnancy disappears), in women 
who were euthyroid prior to pregnancy (16, 18).
MOOD DiSORDERS AnD THYROiD 
AUTOiMMUniTY in GEnERAL 
pOpULATiOn
The association between subclinical hypothyroidism, with and 
without raised TPOAb, and well-being or depression is still con-
troversial, in spite of many studies on this topic. Before moving to 
the abnormal setting, it is appropriate to mention the prevalence 
of thyroid autoantibodies in the general population and their 
association with mood disorders outside of the postpartum 
context.
An interaction between thyroid autoantibodies and mood 
disorders was first valuated in the early 1980s (19). Prevalence 
rates of thyroid autoantibodies in the general population vary 
widely, depending on several reasons, including sex and age 
distribution, geographic origin, variations in the cutoff level 
for antibody positivity (20–22). In an Italian survey, the overall 
prevalence of thyroid autoantibodies, using a cutoff of 1:100 
for both microsomal antibodies and/or thyroid autoantibodies 
was 12.6% (females, 17.3%; males, 7.0%) (23). The reported 
prevalence in the United States healthy population was 13% for 
TPOAb (threshold at ≥0.5 IU/ml) and 11.5% for TgAb (threshold 
at ≥1.0 IU/ml) (21). Overall, the association of circulating thyroid 
autoantibodies with not otherwise specified mood disorders can-
not be considered clearly established.
On the contrary, increased prevalence of circulating thyroid 
autoantibodies is shown in the following forms of mood disor-
ders: treatment-refractory cases (24, 25), severe (26–28), atypical 
depression (29), anxiety disorders or mood disorders (30), and 
depression during early gestation, postpartum, and perimeno-
pause (31–36).
In a population-based study, depression and anxiety were not 
associated with thyroid autoantibodies (37). In 2,049 subjects, 
autoimmune markers (TPOAb, anti-nuclear autoantibodies, 
and several other autoantibodies) were not associated with 
depression symptoms (38). Elevated TPOAb levels cannot be 
used as a general marker of poor well-being or depression, 
as shown in a large population-based Danish study of 8,214 
individuals (39).
With regard to bipolar disorder, sample size was small in 
several studies (40–43). Offspring of bipolar subjects were found 
more susceptible to develop thyroid autoantibodies indepen-
dently from the susceptibility to develop psychiatric disorders 
(44). Autoimmune thyroiditis was suggested as a possible genetic 
biomarker for bipolar disorder in a twin study (45). Hashimoto’s 
encephalopathy can also occur with a bipolar disorder (46, 47), 
being vasculitis-related abnormalities in cortical perfusion one of 
the possible mechanisms (48). High levels of TPOAb were detected 
by Blanchin et al. (49) in the cerebrospinal fluid (CSF) of patients 
with Hashimoto’s encephalopathy. Both sera from their patients 
and monoclonal TPOAb were able to link monkey cerebellar 
cells. Moreover, normal human astrocytes from primary cultures 
binded monoclonal TPOAb. The presence of antigenic targets for 
anti-TSH-receptor IgG on human cortical neurons and TgAb IgG 
in cerebral vasculature was described by Moodley et al. (50).
pOSTpARTUM MOOD DiSORDERS AnD 
THYROiD AUTOiMMUniTY
Risk for postpartum depression and alexithymia showed a direct 
borderline statistically significant correlation with serum TPOAb, 
suggesting that these mood disorders could be neurobehavioral 
consequences of an autoimmune attack (because of the TPOAb 
circulation in the CSF and of their possible cross-reaction with 
cerebral autoantigens) (3).
The PPT is more likely to occur in pregnant thyroid autoan-
tibodies positive women compared to negative women (11). 
Most PPT women develop thyroid dysfunction during the first 
6 months postpartum with initial mild symptoms of hyperthy-
roidism (heat intolerance, palpitations, weight loss, and fatigue) 
and a subsequent hypothyroid phase, frequently associated with 
depression (51). Approximately 50% of PPT women return 
euthyroid by 12 months PP (52).
Much uncertainty remains regarding the relationship between 
PPT and non-psychotic depression in thyroid autoantibodies 
positive euthyroid women. Harris et  al. (53) found no differ-
ence in the rate of postpartum depression between thyroid 
autoantibodies positive women and thyroid autoantibodies 
negative women. However, the same author in 1992 reported an 
association between thyroid autoantibodies positivity and PPT 
(35). Subsequent studies on TPOAb positivity and postpartum 
depression in euthyroid women are controversial, founding 
no association (31, 54) or an association (34, 55). For instance, 
Kuijpens et al. studied prospectively 310 unselected women dur-
ing gestation and up to 36 weeks postpartum (34). The presence of 
TPOAb was independently associated with depression at 12-week 
gestation and at 4 and 12 weeks postpartum (odds ratios between 
2.4 and 3.8) in a prospective study on 310 unselected women (34).
A summary of the English-language literature in the last 
25 years, which addressed the relationship between postpartum 
mood disorders and thyroid autoantibodies, is summarized in 
(Table 1).
In a follow-up study, Harris et al. (35) showed a significantly 
greater depression incidence in 110 thyroid autoantibodies 
positive women (47%) compared with 132 negative women 
(32%) regardless of thyroid dysfunction (Table  1). The same 
author in 2002 reported no difference in postpartum depression 
in TPOAb positive women treated with levothyroxine compared 
with TPOAb positive women given placebo and overall rates of 
major depression of 18.5% and depression in general of 38%, 
providing further evidence linking PPT and TPOAb positivity 
(60). No association was found between thyroid autoantibodies 
and postpartum mood disorders by Lambrinoudaki et al. (59). 
In another study, lower levels of serum FT3 were associated with 
increased incidence of mood disorders in the first postpartum 
week; only TPOAb and TgAb were significantly higher in women 
at risk for postpartum depression compared to women not at 
risk, using EPDS cutoff values of ≥13 or ≥14 (3). The presence of 
TAbLE 1 | Schematic comparison of the last 25 years studies on the relationship between postpartum mood disorders and thyroid autoantibodies.
Reference (56) (57) (58) (35) (34) (59) (3)
Country USA USA Sweden United Kingdom The Netherlands Greece Italy
No. of women 51 119 27 242 291 55 74
Age (years) 18 or older 18–45 Not specified 26.6–25.9 30.8–29.5 32.6 ± 4.2 31.8 ± 4.64
Pregnancy evaluation Yes Yes No Yes Yes No No
Postpartum evaluation Month 1 Month 6 Day 5, week 6, Week 6–8 Weeks 4, 12, 20, 
28, 36
Day 1–4, week 4–6 Day 3
Maternity blues scale (and 
cutoff)
Not evaluated Not evaluated Month 6 Not evaluated Not evaluated PBQ (≥8.2) Not evaluated
Depression scale (and cutoff 
score)
EPDS (≥13) POMS (>20) EPDS (≥12) RDC
EPDS (≥13)
Hamilton (≥15)
HAS
HDS (≥11)
Not specified EPDS (≥11) EPDS (≥13; ≥14)
MADRS (≥15)
Depression score, mean ± SD 6.3 ± 4.8, 5.8 ± 4.4, 
5.1 ± 4.7
EPDS: 8.45 ± 4.4
MADRS: 
14.3 ± 12.3
Depression rate 16.36% POMS-D: 10.9% 15.3% (day 5)
11.7% (week 6)
11.5% (month 6)
RDC depression 47% TAb+ vs 32% TAb−, 
major depression 16% TAb+ vs 11% TAb−
Hamilton 18% TAb+ vs 13% TAb−
EPDS 39% TAb+ vs 27% TAb−
HAS 34% TAb+ vs 30% TAb−
HDS 22% TAb+ vs 17% TAb−
59% TPOAb+ vs 38% 
TPOAb−
24.19% (week 1)
22.8% (week 6)
EPDS (≥13): 20.3%, 
EPDS (≥14): 13.5%
MADRS: 30%
Thyroid function TSH, FT3, FT4 TSH TSH, FT3, FT4 TSH, FT3, FT4 TSH, FT4 TSH, FT3, FT4 TSH, FT3, FT4
Thyroid antibodies TgAb, TPOAb TPOAb TPOAb Tab (not specified) TPOAb TgAb, TPOAb TgAb, TPOAb
Correlation of PPD with thyroid 
indices
EPDS, TSH 
(P = 0.042)
EPDS, TAb 
not specified 
(P = 0.043)
POMS, TPOAb+ 
(P = 0.023)
POMS-D, TPOAb+ 
(P = 0.003)
POMS-A, TPOAb+ 
(P = 0.013)
EPDS, FT3 (OR = 0.8)
EPDS, TSH (OR = 11.30)
EPDS, TPOAb (no 
association)
Hamilton, TAb+ (P = 0.0002)
EPDS, Tab+ (P = 0.031)
HDS, TAB+ (P = 0.003)
PPD%, TPOAb+ 
(P = 0.03)
Mood score, FT4 
(rho −0.3, P ≤ 0.05)
Mood score, TAb 
(no association)
EPDS, TPOAba 
(P = 0.056)
EPDS, TgAb 
(P = 0.05)
EPDS, Edinburgh Postnatal Depression Scale; GHQ, General Health Questionnaire; HAS, Hospital Anxiety Score; HDS, Hospital Depression Score; MADRS, Montgomery and Asberg Depression Rating Scale; OR, odds ratio; PBQ, 
Postpartum Blues Questionnaire; POMS, Profile of Mood States Scale (POMS-A, Anger; POMS-D, Depression); RDC, research diagnostic criteria; TgAb, thyroglobulin; TPOAb, thyroid autoantibodies against thyroperoxidase.
aBoth TgAb and TPOAb levels were greater in depressed vs non-depressed women regardless of EPDS score threshold. Indeed, upon comparing score ≥13 vs score ≤12, TgAb was 38.5 ± 66.3 vs 16.6 ± 35.6 UI/ml (P = 0.05), and 
TPOAb was 26.2 ± 41.7 vs 10.5 ± 19.2 UI/ml (P = 0.05). Upon comparing score ≥14 vs score ≤13, TgAb was 29.9 ± 34.3 vs 19.7 ± 45.3 UI/ml (P = 0.045), and TPOAb was 34.3 ± 49.6 vs 10.5 ± 18.6 UI/ml (P = 0.023).
The rate of TPOAb positiveness in the 10 women with an EPDS score ≥14 was 6.4-fold greater than in 64 women with an EPDS score ≥13 (30.0 vs 4.7%, χ2 = 7.437, P = 0.022).
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thyroid autoantibodies or higher TSH levels during the postpar-
tum period may be related to depressive symptoms or dysphoric 
mood (56). Pregnant TPOAb positive women were shown to 
have higher depressive symptoms during pregnancy, and higher 
depression, anger, and total mood disturbance postpartum, 
regardless of the development of PPT (57).
Sylvén et  al. (58) found an association between the TSH 
level over the clinical cutoff of 4.0 mU/l and the increased risk 
for depressive symptoms at 6 months postpartum in a Swedish 
population-based cohort (OR 11.30, 95% CI 1.93—66.11) 
(Table 1).
DiSCUSSiOn
 Tryptophan catabolites, indoleamine 2,3-dioxygenase, seroto-
nin, and autoimmunity, as possible mediators of the immuno-
inflammation consequences and the oxidative and nitrosative 
stress, may induce postpartum depression (61).
In summary, there is scanty literature on the relationship 
between postpartum mood disorders and thyroid autoantibod-
ies, with data available for the United States and a few European 
countries. Furthermore, these available data stem from differing 
methodologies (e.g., psychometric scales, thyroid autoantibodies 
assays, time and frequency of measurements). Nevertheless, a 
direct, positive, unfavorable relationship does appear. Also stud-
ies evaluating the relationship between thyroid autoantibodies’ 
positivity and postpartum in euthyroid women have been mixed, 
with most of the studies demonstrating a significant association, 
confirmed also by a recent review of Dama et al. (62), who reported 
four of five studies finding a significant associations between 
TPOAb during gestation and postpartum depression (34–36, 57) 
and two of four studies finding links between postpartum TPOAb 
and depression (3, 34).
The cost-effectiveness of integrated perinatal mental health 
care has not been fully evaluated (63, 64) and is still controversial. 
The Edinburgh Postnatal Depression Scale (at a cut point of 16) 
had an incremental cost-effectiveness ratio (ICER) of £41,103 
(€45,398, $67,130) per quality-adjusted life years (QALY) com-
pared with routine care only. The ICER for all other strategies 
ranged from £49,928 to £272,463 per QALY vs routine care only, 
while the probability that no formal identification strategy was 
cost effective was 88% (59%) at a cost-effectiveness threshold 
of £20,000 (£30,000) per QALY. The major determinant of 
cost-effectiveness seems to be the potential additional costs of 
managing women incorrectly diagnosed as depressed (65). Leung 
et al. (66) showed that the use of EPDS as the screening tool and 
the provision of follow-up care had resulted in an improvement 
in maternal mental health at 6 months.
COnCLUSiOn
Negative emotions during pregnancy should be recognized using 
self-report questionnaires as Profile of Mood States Scale, to 
select women at risk for deflected postpartum mood and requir-
ing psychological support. However, more research is required to 
clarify the predictive value and pathophysiological implications 
of the associations between TgAb and/or TPOAb positivity and 
postpartum depression and to support solid evidence of benefit 
and cost-effectiveness of a careful neuropsychological evaluation 
in more 10% of all pregnant women (positive for TPO or Tg 
antibodies).
Future research on postpartum mood disorders should target 
genetic variations of the deiodinases, thyroid hormone trans-
porters, and identification of central nervous system-expressed 
targets of TPOAb (or other coexisting Ab which are specifically 
directed against these targets), particularly in CNS areas engaged 
in depression and/or alexithymia.
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